Sector
PharmaceuticalsOpen
₹570Prev. Close
₹563.95Turnover(Lac.)
₹1,868.4Day's High
₹574Day's Low
₹553.5552 Week's High
₹66552 Week's Low
₹435.25Book Value
₹159.34Face Value
₹10Mkt Cap (₹ Cr.)
2,584.07P/E
0EPS
0.18Divi. Yield
0
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Senores Pharmaceuticals shares closed 6% below their listing price, although they are still up 43% from the IPO price.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 30.51 | 9.82 | 8.74 | 3.8 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 137.61 | 29.11 | 24.95 | 5.67 |
Net Worth | 168.12 | 38.93 | 33.69 | 9.47 |
Minority Interest |
No Record Found
No Record Found
No Record Found
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|
Gross Sales | 214.52 | 35.34 | 14.17 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 214.52 | 35.34 | 14.17 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 2.82 | 3.68 | 0.46 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
SWAPNIL JATINBHAI SHAH
Chairman (Non-Executive)
Sanjay Majmudar
Non Executive Director
Hemanshu Nitinchandra Pandya
Independent Director
Jitendra Babulal Sanghvi
Whole Time Director & COO
Chetan Bipinchandra Shah
Whole Time Director & CFO
Deval Rajnikant Shah
Non Executive Director
Ashokkumar Vijaysinh Barot
Non Executive Director
ARPIT DEEPAKKUMAR SHAH
Independent Director
Naresh Bansilal Shah
Independent Director
Manjula Devi Shroff
Independent Director
Kalpit Rajesh Gandhi
Independent Director
Udayan Choksi
Company Sec. & Compli. Officer
Nidhi Dilipbhai Kapadia
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Senores Pharmaceuticals Ltd
Summary
Senores Pharmaceuticals Limited was originally incorporated as Senores Pharmaceuticals Private Limited through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to Senores Pharmaceuticals Limited upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms. The Regulated Markets business is focused on Regulated Markets of US and Canada. The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs. Further, it develop and manufacture pharmaceutical products across various therapeutic areas for Emerging Markets, having a presence across 43 countries. The Company operate a Critical Care Injectables Business, supplying critical care injectables to hospitals across India through distributors, and manufacture APIs for the domestic market and SAARC countries.In 2021, the Company incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US. It then entered the new segment of API by acquiring Ratnagene Lifescience Priva
Read More
What is the Senores Pharmaceuticals Ltd share price today?
The Senores Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹561.1 today.
What is the Market Cap of Senores Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Senores Pharmaceuticals Ltd is ₹2584.07 Cr. as of 02 Apr ‘25
What is the PE and PB ratio of Senores Pharmaceuticals Ltd?
The PE and PB ratios of Senores Pharmaceuticals Ltd is 0 and 3.55 as of 02 Apr ‘25
What is the 52 Week High and Low of Senores Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Senores Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Senores Pharmaceuticals Ltd is ₹435.25 and ₹665 as of 02 Apr ‘25
What is the CAGR of Senores Pharmaceuticals Ltd?
Senores Pharmaceuticals Ltd's CAGR for 5 Years at N/I%, 3 Years at N/I%, 1 Year at N/I%, 6 Month at 1.24%, 3 Month at -1.29% and 1 Month at 6.31%.
What is the shareholding pattern of Senores Pharmaceuticals Ltd?
The shareholding pattern of Senores Pharmaceuticals Ltd is as follows:
Promoters - 45.76 %
Institutions - 16.04 %
Public - 38.20 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
